Compounded specials product — mucoadhesive buccal films of semaglutide 1mg made by APC Labs for adults transitioning off GLP-1 injection therapy who want maintenance-phase support
Needle-free delivery via buccal absorption bypasses gastric degradation entirely; Novafilm base with menthol permeation enhancer allows semaglutide to enter systemic circulation through inner cheek
Weekly or twice-weekly maintenance positioning — deliberately lower intensity than injectable weight-loss dosing (2.4mg weekly Wegovy); aims to reduce food noise and support weight stability after injection cessation
Semaglutide contraindications matter: medullary thyroid cancer, MEN2, previous pancreatitis, pregnancy all rule out use; prescriber assessment before supply is essential, not optional
Weight loss is genuinely hard. After all, obesity is a chronic condition driven by complex hormonal, metabolic, psychological, and environmental factors — not just “willpower.” The arrival of GLP-1 receptor agonists (semaglutide, tirzepatide) has transformed weight management for many patients, with STEP trials showing 15-20% weight loss over 68 weeks in appropriate patients.
Weight is regained after stopping GLP-1s
However, the trials also showed something equally important: when patients stop GLP-1 injections, they typically regain most of the weight lost. The STEP 1 extension trial showed that patients regained approximately two-thirds of the weight they had lost within a year of stopping semaglutide. SURMOUNT-4 showed similar patterns for tirzepatide.
So the weight maintenance phase after injection therapy is genuinely one of the most vulnerable periods in the weight management journey.
Weight maintenance phase
SLIM Films fit specifically into this maintenance phase. Specifically, they provide lower-intensity ongoing GLP-1 receptor engagement through a needle-free buccal delivery format, aiming to reduce the food noise return and appetite dysregulation that many patients experience when stopping injections cold. As a result, they offer a middle path between continuing full-dose weekly injections indefinitely and stopping all pharmacological support at once.
However, honest framing matters: SLIM Films aren’t equivalent to full-dose weekly injections for active weight loss, they don’t guarantee prevention of weight regain, they’re an unlicensed compounded product with less specific evidence than licensed injectable or oral formulations, and they work best alongside continued attention to dietary patterns, physical activity, sleep, and stress management. So they’re a specific tool for a specific clinical scenario, used appropriately alongside comprehensive maintenance approaches.
Stage 2: Active weight loss — full-dose weekly injectable GLP-1 (semaglutide 2.4mg weekly as Wegovy, or tirzepatide up to 15mg weekly as Mounjaro)
Stage 3: Weight loss consolidation — continued injections at maintenance doses
Stage 4: Transition to maintenance — reducing injection dose or switching to alternative maintenance approaches
Stage 5: Maintenance phase — lower-intensity GLP-1 support (SLIM Films fit here) plus continued lifestyle work
Stage 6: Gradual reduction — some patients may reduce or stop maintenance therapy as lifestyle becomes established
Stage 7: Long-term monitoring — ongoing review, weight tracking, and pharmacological support if needed
Stage 8: Re-treatment cycles if needed — many patients need multiple treatment cycles across their lifetime given the chronic nature of obesity
So SLIM Films sit at Stage 5 — the maintenance phase after active weight loss has been achieved. In short, they’re specifically designed for the transition and maintenance period, not the active weight loss phase.
SLIM Films vs continuing weekly injections (Wegovy, Ozempic, Mounjaro)
Different roles in the treatment journey:
SLIM Films: maintenance-level dosing (1mg buccally weekly or twice weekly)
In contrast, Wegovy: 2.4mg weekly subcutaneous injection for active weight management
Ozempic: 0.5-1mg weekly subcutaneous for type 2 diabetes
Mounjaro: up to 15mg weekly subcutaneous (tirzepatide, dual GIP/GLP-1)
Injections have extensive clinical trial evidence
Injections deliver higher, more consistent plasma concentrations
Injections are licensed products with regulatory approval for specific indications
SLIM Films are unlicensed compounded specials
If actively losing weight is the goal, injections typically fit better
If maintaining reached weight is the goal, lower-intensity options like SLIM Films may fit
In general, continue injections during active weight loss; consider SLIM Films only after reaching maintenance
SLIM Films vs Rybelsus (oral semaglutide tablets)
Two non-injection semaglutide options:
SLIM Films: buccal absorption, 1mg weekly to twice weekly
In contrast, Rybelsus: oral tablet, 3-14mg daily
Rybelsus is a licensed product (Novo Nordisk) for type 2 diabetes
Rybelsus needs empty stomach and specific water volume for absorption
Rybelsus daily dosing requires consistent routine
SLIM Films weekly dosing suits different routine
Both bypass injections
Rybelsus has more clinical trial evidence
SLIM Films are compounded specials with less specific evidence
Rybelsus isn’t licensed for weight management (though prescribed off-label sometimes)
In general, Rybelsus fits daily oral tolerance; SLIM Films fit weekly maintenance preference
SLIM Films vs THIN sublingual sprays
Two Medical Mojo non-injection GLP-1 options:
SLIM Films: buccal mucoadhesive film, semaglutide
In contrast, THIN sprays: sublingual spray, semaglutide or tirzepatide
Both are compounded specials at Medical Mojo
Both bypass injection route
Films dissolve over minutes; sprays absorb quickly
Films offer sustained mucosal contact through mucoadhesion
Sprays offer faster onset from sublingual absorption
Individual patient preference varies
In general, films suit those who prefer prolonged contact and don’t want spray sensation; sprays suit those preferring quick dosing
SLIM Films vs stopping GLP-1 completely
Two different post-injection strategies:
SLIM Films: continued lower-intensity GLP-1 receptor engagement
In contrast, complete discontinuation: no ongoing pharmacological support
STEP 1 extension data: patients discontinuing regained roughly two-thirds of weight lost within a year
SURMOUNT-4 data: similar pattern for tirzepatide
Complete discontinuation is genuinely more challenging for weight maintenance
However, some patients successfully transition to lifestyle-only maintenance
Exercise-based approaches: increased energy expenditure
Combined approaches often work best
Individual response varies significantly
Who these films may suit well
This product may suit:
Adults who have completed a course of GLP-1 injection therapy
Adults who have reached their weight goal or a weight they want to maintain
Adults concerned about weight regain risk after stopping injections
Adults experiencing return of food noise since stopping injections
Adults with needle phobia not wanting to continue injections
Adults who dislike weekly injection routine
Adults wanting a discreet, portable option
Adults committed to ongoing lifestyle work alongside pharmacological support
Adults understanding the compounded specials status
Adults engaged with prescriber-led review and monitoring
Who might suit other options better
Other options may suit better for:
Adults still in active weight loss phase (continue full-dose injections)
Adults who haven’t yet tried licensed weight management options
Adults with medullary thyroid cancer or family history (contraindicated)
Adults with multiple endocrine neoplasia syndrome type 2 (contraindicated)
Adults with previous pancreatitis (contraindicated or high caution)
Adults with severe gastrointestinal disease including gastroparesis
Adults with severe hepatic impairment
Adults with severe renal impairment
Adults with active gallbladder disease
Adults with proliferative diabetic retinopathy
Adults with active eating disorders (needs specialist input)
Adults who are pregnant, planning pregnancy, or breastfeeding
Adults with active oral pathology preventing buccal absorption
Adults preferring licensed products over compounded specials
Adults who successfully maintained weight without pharmacological support previously
Medical Mojo supply
This is a compounded medicinal product. So supply only happens after our UK-qualified prescriber reviews your situation thoroughly. The consultation covers:
Your weight management history
Details of GLP-1 injection therapy already completed
Duration and doses of previous injection therapy
Weight lost during injection therapy
Time since stopping injections and current weight trajectory
Return of food noise or appetite dysregulation
Personal and family history of medullary thyroid cancer or MEN2
History of pancreatitis
Gallbladder history
Any relevant medical history
Current medications
Pregnancy status if applicable
Understanding of the compounded specials status
Realistic expectations for maintenance vs active loss
Ongoing lifestyle work
Monitoring plan
In short, this isn’t a checkbox consultation — it’s a clinical assessment about the right approach for your maintenance phase. So we take time to make sure SLIM Films fit your specific situation, and to explore whether alternative approaches might suit better.
Key features and specs
Active ingredient: semaglutide 1mg per film
Class: GLP-1 receptor agonist
Form: mucoadhesive buccal film
Base: Novafilm (vegetarian-suitable)
Permeation enhancer: menthol
Route: buccal (against inner cheek)
Dissolution time: typically minutes
Frequency: once or twice weekly (as prescribed)
Positioning: weight maintenance, not active weight loss
Legal status: unlicensed compounded special
Manufacturer: APC Labs Ltd (GPhC 9012301), Southampton, to Medical Mojo prescriber order
Storage: room temperature, in original packaging
Shelf life: as determined by stability data on supply
Not for: active weight loss phase, pregnancy, breastfeeding, medullary thyroid cancer, MEN2, previous pancreatitis
SLIM Films Semaglutide 1mg — Buccal GLP-1 Maintenance Films for Weight Stability After Injection
This is a compounded medicinal product — mucoadhesive buccal films containing semaglutide 1mg (a GLP-1 receptor agonist), designed to be placed against the inner cheek and left to dissolve.
So each film delivers semaglutide directly through the buccal mucosa, bypassing the digestive system entirely — a needle-free maintenance option for adults transitioning off weekly GLP-1 injections who want to reduce the risk of weight regain and continued food noise.
As a result, SLIM Films fit a specific clinical scenario: patients who’ve completed a course of GLP-1 injections (Wegovy, Ozempic, Mounjaro), reached their weight goal, and want lower-intensity ongoing support to maintain their progress and quieten hunger signals without returning to injections. Important: this is an unlicensed compounded medicine, and semaglutide has genuine cardiovascular, pancreatitis, and thyroid contraindications — so prescriber assessment is essential before supply. Available at Medical Mojo after full clinical review.
At Medical Mojo, we believe in treatment that fits the person — but only where it’s honest, safe, and consented to.
This page covers what SLIM Films are, how the buccal delivery format works differently from injections and oral semaglutide (Rybelsus), who they may suit for GLP-1 maintenance, and the practical points that matter — the realistic clinical role of maintenance dosing, the honest framing around weight regain after GLP-1 cessation, and when injection continuation or complete discontinuation might suit better than maintenance films.
Regulatory position — please read first
Before going further, we want to be straight with you about four things:
First, SLIM Films are an unlicensed compounded medicinal products manufactured to prescriber order under GPhC-regulated compounding standards by our compounding partner APC Labs Ltd (GPhC 9012301, Southampton). So they aren’t licensed medicines like Wegovy, Ozempic, or Rybelsus — instead, they’re compounded medicines made available under the specials pathway where a prescriber judges an alternative formulation is needed to meet a specific clinical need.
Second, this product isn’t a replacement for full-dose GLP-1 injection therapy in patients still needing active weight loss treatment. If you’re still working towards a weight goal and haven’t reached maintenance yet, continued injection therapy at appropriate doses typically fits your situation better. SLIM Films specifically target the maintenance phase — after injection therapy has achieved its main effect.
Third, semaglutide has important safety considerations. Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, previous pancreatitis, severe gastrointestinal disease, and pregnancy are all reasons semaglutide can’t be used. So our prescriber assesses these before first supply — this isn’t a formality.
Fourth, the evidence base for buccal semaglutide specifically is limited. While the semaglutide molecule itself has extensive evidence (STEP trials, SUSTAIN trials, SELECT trial for cardiovascular outcomes), the buccal delivery format has less specific clinical trial data compared to subcutaneous injection or oral tablet formulations. As a result, our prescriber discusses what this means for realistic expectations, dose response variability, and monitoring approach before supply.
If any of these points raise concerns, please talk to our prescriber before proceeding. After all, GLP-1 maintenance therapy needs proper clinical judgement — not just prescription fulfilment.
Five key takeaways
SLIM Films are compounded medicines — mucoadhesive buccal films of semaglutide 1mg made by GPhC-regulated compounding partner APC Labs to individual prescriber order, specifically for adults transitioning off GLP-1 injection therapy who want maintenance support
The buccal delivery format uses a proprietary Novafilm base with menthol as a permeation enhancer. Films adhere to the inner cheek and dissolve over minutes, delivering semaglutide through the buccal mucosa directly into the systemic circulation, bypassing gastric degradation entirely
Weekly maintenance positioning — typical use is one to two films per week, deliberately less intensive than the daily oral or weekly injectable dosing used for active weight loss. This maintenance dose aims to provide a steady background level of GLP-1 receptor activity to help maintain weight loss and quieten food noise
Needle-free option for needle-phobic patients or those who dislike the practical routine of weekly injections. Discreet, portable, no cold chain required, no injection technique needed. Films dissolve in the mouth without needing water
Important safety considerations: semaglutide is contraindicated in medullary thyroid carcinoma, MEN2 syndrome, previous pancreatitis, pregnancy, and breastfeeding; caution needed with gallbladder disease, gastroparesis, and diabetic retinopathy; prescriber assessment before supply is essential, not optional
Why choose Medical Mojo for GLP-1 maintenance
At Medical Mojo, our approach starts with a simple idea: treatment should fit the person, not force the person to fit the system.
Dr Rosalind Jex
Our service is shaped by the philosophy of Dr Rosalind Jex, our brand pharmacist.
Dr Rosalind represents the spirit of the pharmacy: evidence-led, community-rooted, and willing to challenge the one-size-fits-all approach to medicine. She is named in honour of two pioneering women in science: Rosalind Franklin, the chemist and X-ray crystallographer whose work revealed the structure of DNA; and Sophia Jex-Blake, the first female doctor in the UK, who fought the medical establishment for the right to practise.
In her steampunk laboratory, Dr Rosalind works against pharma’s standardised approach to medicine. In the real world, she represents what we stand for. Her view is straightforward: you are not broken. The system is. And we are here to change that.
The maintenance phase deserves proper attention
Most weight management services stop paying attention once the weight has come off. Medical Mojo is different. So we recognise that:
The maintenance phase is where most weight management fails
Patients are often discharged at exactly the point support matters most
Weight regain after stopping GLP-1 therapy is the expected pattern, not the exception
Ongoing support should be proportionate, not maximal
The lowest effective level of support is usually the right target
Some patients need no ongoing therapy at all, and we’ll say so
Prescriber judgement about intensity matters
Honest framing about 1mg vs 2mg
Lower isn’t automatically better, and neither is higher:
1mg provides gentler appetite regulation than 2mg
1mg has lower rates of gastrointestinal side effects
Some patients find 1mg entirely sufficient
Others find it too light and need 2mg
Individual factors determine the right strength
Starting on 1mg and stepping up if needed is often sensible
Stepping down from 2mg to 1mg is also a reasonable path
Honest framing about 1mg vs injection continuation
Different pharmacokinetics matter:
Buccal delivery provides less consistent plasma concentrations than injection
Injection continuation has a stronger evidence base
1mg SLIM Films fit needle-free preference at maintenance intensity
If you’re still actively losing weight, injection therapy usually fits better
If your weight starts drifting on 1mg, that’s information worth acting on
Honest framing about GLP-1 discontinuation and weight regain
The data:
STEP 1 extension trial: patients regained approximately two-thirds of weight lost within a year of stopping
SURMOUNT-4: similar pattern for tirzepatide
This isn’t a treatment failure, it reflects the chronic nature of obesity biology
Obesity is now understood as a chronic condition needing ongoing management
Many patients need long-term or intermittent pharmacological support
However, some patients do maintain successfully without it
Individual factors matter significantly
Honest framing about the compounded medicine status
What this means:
SLIM Films are unlicensed compounded medicines — not licensed medicines like Wegovy or Ozempic
Made under GPhC-regulated compounding manufacturing standards
Individual prescriber judgement basis for supply
Less specific evidence base than licensed products
MHRA regulates unlicensed compounded medicines differently from licensed products
The compounding pathway exists precisely because alternative formulations meet specific clinical needs
However, licensed products preferred where they meet the need
Maintenance and the bigger picture
Weight management rarely sits in isolation. So our prescriber can discuss:
Comprehensive approach
Dietary patterns that sustain outcomes
Physical activity for weight management
Sleep quality and weight regulation
Stress and emotional eating
Menstrual cycle and hormonal factors
Menopause and weight regulation
Cardiovascular risk maintenance benefits
Metabolic markers monitoring
When to consider stepping up or down
When to transition off pharmacological support
When to consider return to injection therapy
Sometimes weight maintenance is one part of a wider health picture worth talking through.
Prescriber support before and after supply
Our team is here to discuss:
Whether SLIM Films 1mg fit your specific situation
Whether 2mg would suit you better
Alternative approaches
Comprehensive lifestyle work alongside pharmacological support
Correct application technique
Realistic expectations at maintenance dosing
Monitoring approach
What to do if you don’t feel enough effect
What to do if side effects are troublesome
When to review or adjust strength
Trust earned, not claimed
We are GPhC-regulated, and our content is grounded in the licensed Wegovy, Ozempic, and Rybelsus Summary of Product Characteristics documents (Novo Nordisk) for the semaglutide molecule characteristics, STEP trial evidence base for semaglutide efficacy in weight management, STEP 1 extension trial for post-cessation weight regain data, SELECT trial for cardiovascular outcomes, SURMOUNT-4 for the equivalent tirzepatide data, MHRA guidance on unlicensed compounded medicine manufacturing, GPhC standards for pharmacy compounding, and the real experience of patients managing weight after GLP-1 injection therapy.
If SLIM Films 1mg aren’t the right answer for your situation, we’ll tell you honestly. After all, getting the right approach matters more than fulfilling a request.
How supply works
This is a compounded medicine. So the supply process has proper clinical steps.
How our service works
Complete the detailed weight management consultation on medicalmojo.co.uk
Our UK-qualified prescriber reviews your weight management history and current situation
The prescriber assesses whether 1mg is appropriate vs 2mg or other approaches
If approved, the prescriber issues a compounding order
APC Labs compounds your specific supply under GPhC-regulated compounding manufacturing
Your order is dispatched in plain, discreet packaging
Free prescriber support is available throughout treatment
Regular review to assess response and consider dose adjustments
What the consultation covers
Supply only happens after our UK-qualified prescriber reviews your situation thoroughly. The consultation covers:
Your weight management history
Details of GLP-1 injection therapy already completed
Duration and doses of previous injection therapy
Weight lost during injection therapy
Time since stopping injections and current weight trajectory
Return of food noise or appetite dysregulation
Personal and family history of medullary thyroid cancer or MEN2
History of pancreatitis
Gallbladder history
Any relevant medical history
Current medications
Pregnancy status if applicable
Understanding of the compounded status
Realistic expectations for maintenance vs weight-loss dosing
Ongoing lifestyle work
Monitoring plan
In short, this isn’t a checkbox consultation. It’s a clinical assessment about the right approach for your specific situation. So we take time to make sure maintenance dosing genuinely fits where you are.
When other options might suit better
If SLIM Films 1mg aren’t right, we’ll explain why. Other options may include:
SLIM Films 2mg — for higher-intensity ongoing support
SLIM Films Tirzepatide 5mg — for dual GIP/GLP-1 mechanism support
Continued Wegovy injections at maintenance dose
Continued Ozempic injections (for diabetic patients)
Reduced-dose weekly injections
Extended interval injection (every 2 weeks or monthly)
Rybelsus oral tablets
THIN sublingual sprays (Medical Mojo alternative non-injection option)
Specialist obesity medicine referral for complex cases
Active ingredient
Each SLIM Film contains:
Semaglutide 1mg (GLP-1 receptor agonist)
Menthol (permeation enhancer)
Novafilm base (mucoadhesive film-forming excipient — suitable for vegetarians)
Why semaglutide
Semaglutide is one of the most extensively studied GLP-1 receptor agonists:
Human GLP-1 analogue (94% amino acid sequence similarity)
Long half-life (approximately 165 hours / around 7 days)
Allows weekly rather than daily dosing
GLP-1 receptor agonist with effects on appetite regulation, gastric emptying, and glucose metabolism
Licensed as Ozempic for type 2 diabetes and Wegovy for weight management
Also licensed as Rybelsus (oral tablet form)
STEP trials (STEP 1-8) demonstrated efficacy in weight management
SUSTAIN trials demonstrated glycaemic control efficacy
SELECT trial demonstrated cardiovascular outcome benefits in overweight patients with established cardiovascular disease
Well-characterised safety profile from extensive post-marketing surveillance
In short, semaglutide is one of the reference GLP-1 receptor agonists with a strong evidence base. After all, when a molecule has been studied across multiple large randomised controlled trials with consistent efficacy signals, it earns its place at the centre of GLP-1 pharmacotherapy.
Why the 1mg strength
The 1mg dose is deliberately maintenance-level:
Below the 2.4mg weekly injectable dose used for active weight management with Wegovy
Comparable to standard Ozempic maintenance dosing for diabetes (0.5-1mg weekly)
Positioned for maintenance rather than active loss phase
Accounts for likely variability in buccal absorption compared to subcutaneous injection
Allows once or twice weekly dosing based on individual response
Balances effect with tolerability for long-term use
After all, maintenance dosing is genuinely different from active weight loss dosing. So the 1mg strength reflects the specific clinical scenario the product targets — supporting weight stability, not driving further weight loss.
Why the buccal film format
The buccal route offers specific practical advantages:
Needle-free — no injection technique required
No cold chain — films stable at room temperature
Portable — fits in a pocket or handbag
Discreet — usable in most settings without attracting attention
Bypasses gastric acid and digestive enzymes that would degrade semaglutide
Mucoadhesive coating allows prolonged contact with buccal mucosa for absorption
Rapid dissolve — films typically dissolve within minutes
No swallowing required — suitable for patients with dysphagia
Doesn't require water or food
In short, the buccal route addresses the practical barriers many patients face with injectable GLP-1s: needle discomfort, cold storage requirements, injection technique anxiety, and the routine burden of weekly injection preparation. So while it doesn't replace injections for active weight loss, it offers a genuinely different practical profile for maintenance-phase patients.
Why menthol as permeation enhancer
Menthol serves a specific pharmaceutical function:
Enhances permeability of the buccal mucosa
Increases absorption of the semaglutide through the buccal tissue
Well-established as a permeation enhancer in oral and mucosal drug delivery
Provides mild pleasant taste
Provides mild sensory feedback confirming film placement
Recognised as safe in this application
After all, semaglutide is a large peptide molecule — without permeation enhancement, buccal absorption would be limited. So menthol isn't just flavouring; it's functional formulation.
Why Novafilm base
Novafilm is a proprietary mucoadhesive film-forming platform:
Adheres to the buccal mucosa on contact
Prevents film displacement during dissolution
Provides sustained release of active over the dissolution period
Suitable for vegetarians (contains no animal-derived ingredients)
Well-tolerated on the buccal mucosa
Dissolves cleanly without residue
Compatible with menthol permeation enhancement
Other ingredients
Additional excipients in the Novafilm base support film integrity, adhesion, and controlled dissolution.
Complete excipients list is provided with each supply. So mention any known allergies or sensitivities during your consultation.
Pack details
SLIM Films come as:
Individually foil-wrapped single-dose films
Typically supplied in packs matching prescribed frequency (4 or 8 film packs)
Amber blister backing to protect from light
Each film is single-use
Sealed until use
How they're made
Important transparency points:
Compounded to prescriber order at APC Labs Ltd (GPhC 9012301)
Made under GPhC compounding standards
Semaglutide sourced from approved API supplier
Quality control includes content uniformity, dissolution, and microbial testing
Room temperature storage suitable
Shelf life determined by stability data
Batch documentation retained per specials manufacturing standards
After all, this is compounded rather than industrially manufactured. So the regulatory pathway is genuinely different from licensed products like Wegovy or Ozempic — and being clear about that matters.
What are SLIM Films for?
SLIM Films are designed for weight maintenance in adults who have completed a course of GLP-1 injection therapy and reached their weight loss goal. So the target scenario isn't active weight loss — it's the post-injection phase where patients want ongoing support to maintain the progress they've made. As a result, they fit a specific transition point in the weight management journey, not the initial treatment phase.
Who might SLIM Films suit?
This product may suit:
Adults who have completed a course of GLP-1 injection therapy (semaglutide, tirzepatide, liraglutide)
Adults who have reached their target weight or a weight they want to maintain
Adults transitioning off active weight loss therapy who want lower-intensity maintenance support
Adults concerned about weight regain after stopping injections
Adults experiencing return of food noise after stopping injections
Adults with needle phobia who want ongoing GLP-1 support
Adults who dislike the practical routine of weekly injections
Adults wanting a discreet, portable option
Adults committed to lifestyle changes alongside pharmacological support
Adults without contraindicating conditions (medullary thyroid cancer, MEN2, previous pancreatitis)
Adults not currently pregnant, planning pregnancy, or breastfeeding
Adults understanding this is an unlicensed compounded product
Adults engaged with prescriber-led review and monitoring
What SLIM Films may help with
Based on the pharmacology of semaglutide and the maintenance-dose positioning:
Ongoing appetite regulation after injection cessation
Reduction of food noise (intrusive thoughts about food)
Snack prevention through steadier satiety signalling
Support for weight maintenance during the vulnerable post-injection period
Bridging the gap between active weight loss and long-term lifestyle-only maintenance
Reduced portion sizes at meals through earlier satiety
Support during high-risk periods (stress, travel, hormonal changes)
Ongoing needle-free GLP-1 receptor engagement
Important honesty point: SLIM Films support weight maintenance — they don't guarantee it. After all, weight maintenance is genuinely multifactorial. Lifestyle changes (dietary patterns, physical activity, sleep, stress management) remain the foundation of long-term outcomes. Pharmacological support helps, but it doesn't replace the underlying work. Realistic expectations matter.
What SLIM Films don't claim to do
Honest framing matters:
They don't produce the active weight loss effect of full-dose weekly injections
They don't guarantee prevention of weight regain (lifestyle factors matter)
They don't replace the need for dietary changes and physical activity
They don't address underlying causes of weight gain (hormonal, metabolic, psychological)
They don't work overnight — steady state builds over weeks
They don't treat diabetes as a licensed indication (though semaglutide is licensed for T2 diabetes as Ozempic)
They don't work in medullary thyroid cancer or MEN2 syndrome — contraindicated
They don't have the extensive clinical trial evidence of licensed GLP-1 formulations
How SLIM Films work
Understanding the mechanism helps explain both what to expect and why buccal delivery differs from other routes.
The GLP-1 mechanism
Semaglutide targets multiple pathways:
Binds to GLP-1 receptors in hypothalamus (appetite regulation)
Increases satiety signalling
Reduces hunger signalling
Slows gastric emptying (fullness for longer after meals)
Reduces food noise (intrusive thoughts about food)
Affects reward pathways for food (reduced food reward)
Improves insulin secretion in response to meals
Reduces inappropriate glucagon secretion
Improves glycaemic control
May have direct cardiovascular protective effects
How the buccal film works
Film placed against inner cheek mucosa
Mucoadhesive Novafilm base attaches to buccal tissue
Film begins to hydrate from saliva
Menthol enhances permeability of buccal mucosa
Semaglutide gradually released as film dissolves
Absorbed through buccal mucosa into systemic circulation
Bypasses gastric acid and digestive enzymes entirely
Bypasses first-pass hepatic metabolism
Reaches GLP-1 receptors throughout the body
Effects on appetite, gastric emptying, and glucose develop over hours to days
In short, buccal delivery is a genuine drug delivery innovation for peptides — bypassing the gastric degradation that makes oral peptide delivery so challenging. After all, this is why traditional GLP-1 delivery has been injection-based.
Long half-life (approximately 165 hours / around 7 days)
Steady state plasma concentrations achieved over 4-5 weeks
Weekly dosing gives smooth plasma profile
Twice-weekly dosing gives higher steady state
Buccal absorption dosing accounts for likely bioavailability differences
Individual response variability means dose frequency may be adjusted
Onset timeline
What to expect:
First week: no obvious effect for most patients
Weeks 2-4: appetite regulation may begin to develop
Weeks 4-8: steady state plasma concentrations achieved
Beyond 8 weeks: full maintenance effect established
Individual variation is significant
Some patients notice food noise reduction earlier
How to use SLIM Films
Correct technique matters for effectiveness. So take a few minutes to understand the technique before your first film.
Standard technique
Wash your hands thoroughly
Remove one film from its foil pouch immediately before use
Handle the film by the edges — don't touch the central area if possible
Open your mouth and dry the inner cheek surface slightly with your tongue
Place the film against the inner cheek, pressing lightly for a few seconds
The mucoadhesive base will attach to the cheek
Leave the film in place — don't chew or swallow
The film will dissolve over minutes
Avoid eating or drinking for 15-30 minutes after
Don't rinse your mouth immediately after
Practical tips
Alternate cheeks between doses to avoid local irritation
Best applied at a consistent time (allows routine)
Doesn't need to be at any particular time relative to meals
Menthol sensation confirms placement — this is normal
If film comes loose before dissolution, discuss with prescriber
Rinse mouth with warm water to increase local blood flow
Frequency
Typical starting frequency: one film per week
Can increase to two films per week if additional support needed
Space by at least 3 days between doses
Follow prescriber's specific instructions
What to combine with
Comprehensive maintenance often needs multiple elements:
Continued attention to dietary patterns
Regular physical activity
Adequate sleep
Stress management
Regular self-monitoring (weight, measurements, or wellbeing markers)
Behavioural strategies for high-risk situations
Support networks and accountability
What to avoid
Chewing or swallowing the film
Eating or drinking immediately after application
Rinsing your mouth immediately after
Combining with other GLP-1 formulations
Using during pregnancy or breastfeeding
Using without prescriber review during treatment
If a film comes loose
If it comes off before dissolving, discuss with prescriber
Don't automatically use another one
Note timing and circumstances for pharmacist advice
Storage
Store at room temperature
Keep in original packaging
Away from direct heat and moisture
Keep out of sight and reach of children
Use by expiry date on packaging
Warnings and precautions
Semaglutide has important safety considerations. So the warnings section is longer and more important than for many products.
Don't use SLIM Films if you
Have personal or family history of medullary thyroid carcinoma
Have multiple endocrine neoplasia syndrome type 2 (MEN2)
Have had pancreatitis
Have severe gastrointestinal disease including gastroparesis
Have severe hepatic impairment
Have severe renal impairment (end-stage)
Are pregnant or planning pregnancy
Are breastfeeding
Have known allergy to semaglutide or any excipient
Have active oral pathology that would prevent absorption
Have active eating disorder
The pancreatitis warning
Rare but serious:
GLP-1 agonists have been associated with pancreatitis in post-marketing data
Absolute risk is low but real
Previous pancreatitis is a contraindication
Symptoms: severe upper abdominal pain radiating to back, nausea, vomiting
Stop treatment and seek urgent medical assessment if pancreatitis suspected
The thyroid warning
Contraindication basis:
Rodent studies showed thyroid C-cell tumours with GLP-1 agonists
Human relevance unclear but precautionary contraindication in medullary thyroid cancer and MEN2
Family history of medullary thyroid cancer is a contraindication
New neck lumps or thyroid symptoms during treatment need assessment
The gallbladder warning
Increased risk documented:
GLP-1 agonists increase risk of gallstone-related events
Weight loss itself also increases gallstone risk
Symptoms: right upper abdominal pain, particularly after fatty meals
Active gallbladder disease is a relative contraindication
The diabetic retinopathy warning
Relevant for diabetics:
Rapid glycaemic changes can worsen diabetic retinopathy
Proliferative retinopathy is a relative contraindication
Retinal review recommended before starting in diabetics with retinopathy
The eating disorder consideration
Important safeguard:
Active eating disorders (anorexia, bulimia) are contraindications
Past eating disorders warrant specialist input before GLP-1 use
Body image dysmorphia warrants careful assessment
Prescriber screens for eating disorder markers
Use with care if you
Have mild-to-moderate renal impairment
Have mild-to-moderate hepatic impairment
Have gastroparesis or slowed gastric emptying
Have gastro-oesophageal reflux disease
Have type 1 diabetes (semaglutide not licensed for this)
Are on insulin or sulphonylurea (hypoglycaemia risk)
Are over 75 years old (limited data in very elderly)
Have had bariatric surgery (specialist input recommended)
Pregnancy and breastfeeding
Not for use during pregnancy or planning pregnancy
Not for use during breastfeeding
Stop treatment at least 2 months before planned conception
Effective contraception during use in women of childbearing age
Driving and machinery
Generally doesn't affect driving:
SLIM Films don't typically affect driving
Hypoglycaemia risk if used alongside diabetic medications
Nausea during initial dosing may affect concentration
When to seek urgent medical help
Severe upper abdominal pain (possible pancreatitis)
Right upper abdominal pain (possible gallstones)
Signs of severe allergic reaction (facial swelling, breathing difficulty)
New neck lumps or persistent hoarseness
Persistent severe vomiting
Signs of dehydration
Vision changes (in diabetics)
Side effects
Semaglutide has a well-characterised side effect profile from licensed injectable and oral formulations.
Common side effects
Nausea (especially initially)
Vomiting
Diarrhoea
Constipation
Abdominal pain
Dyspepsia (indigestion)
Reduced appetite
Fatigue
Headache
Local mucosal irritation (buccal-specific)
Menthol taste sensation
Less common side effects
Hypoglycaemia (if used alongside diabetic medications)
Belching
Flatulence
Bloating
Gastro-oesophageal reflux
Injection-site-equivalent local reactions at buccal site
Altered taste
Dizziness
Rare side effects
Acute pancreatitis
Gallbladder events (gallstones, cholecystitis)
Acute kidney injury (associated with dehydration from vomiting/diarrhoea)
Diabetic retinopathy worsening
Allergic reactions
Elevated pancreatic enzymes
Very rare side effects
Severe allergic reactions (anaphylaxis)
Angioedema
The GI symptoms question
Common and usually manageable:
Nausea and other GI symptoms are the most common side effects
Typically improve over weeks as the body adjusts
Small frequent meals help
Avoiding high-fat meals helps
Adequate hydration important
If severe or persistent, discuss with prescriber
Stop and seek urgent medical help if
Severe upper abdominal pain
Signs of severe allergic reaction
Persistent severe vomiting causing dehydration
Vision changes
New neck lumps
Yellow Card reporting
If you experience any side effects, you can report them via the MHRA Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. Reporting side effects helps improve safety information for all patients.
Drug interactions
Semaglutide has several important interactions to consider.
Interactions requiring care
Insulin — hypoglycaemia risk, may need insulin dose reduction
Immediate eating or drinking may affect film dissolution
Water for essential hydration is fine
Full meals best avoided until film has dissolved
Which cheek should I use?
Alternate cheeks:
Alternate between doses to prevent local irritation
Either cheek works — no clinical difference
Choose whichever is easier for placement
How long can I stay on SLIM Films?
Depends on individual factors:
Some patients use short-term (months) during transition off injections
Some patients use longer-term for ongoing maintenance support
Regular prescriber review essential
Not intended as permanent daily use replacement for lifestyle work
Can I combine with injections?
No — don't combine:
Don't combine SLIM Films with any other GLP-1 formulation
This would cause excessive dosing
Choose one approach at a time
Can I use them in pregnancy?
No:
Semaglutide contraindicated in pregnancy
Stop treatment at least 2 months before planned conception
Effective contraception during use
Contact prescriber if pregnancy occurs during treatment
What if I get nausea?
Common but usually manageable:
Nausea is common with GLP-1 agonists
Usually improves over weeks
Small frequent meals help
Avoid high-fat meals
Adequate hydration
If severe or persistent, discuss with prescriber
What if I get severe abdominal pain?
Stop and seek assessment:
Severe upper abdominal pain radiating to the back can indicate pancreatitis
Right upper abdominal pain can indicate gallstones
Both need urgent medical assessment
Stop SLIM Films pending assessment
How should I store them?
Room temperature
In original packaging
Away from direct heat and moisture
Keep out of reach of children
Use by expiry date
Is my packaging discreet?
Plain packaging with no mention of contents
Suitable for delivery to home or workplace
How do I order from Medical Mojo?
Complete the weight management consultation on medicalmojo.co.uk. Our prescriber will review your treatment history and current situation, then arrange compounding by APC Labs if suitable. Your order goes out in plain, discreet packaging with support available throughout your treatment.
Disclaimer
This page is for information only and isn't a substitute for personal medical advice.
SLIM Films are an unlicensed compounded specials product containing semaglutide, made available under the specials pathway based on individual prescriber judgement.
Semaglutide is contraindicated in medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, previous pancreatitis, pregnancy, and breastfeeding.
Prescriber assessment before use is essential.
Signs of pancreatitis (severe upper abdominal pain radiating to back with nausea and vomiting) need urgent medical assessment.
Signs of severe allergic reaction (facial swelling, breathing difficulty, widespread rash) need immediate medical attention (999).
SLIM Films are positioned for maintenance phase after GLP-1 injection therapy, not for active weight loss — licensed injectable products typically fit active treatment phase better.
This product should be used alongside comprehensive lifestyle approaches to weight maintenance.
References
1] Wilding, J.P.H. et al. (2022) ‘Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension’, Diabetes, Obesity and Metabolism, 24(8), pp. 1553–1564. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542252/ (Accessed: 4 July 2026).
[2] Aronne, L.J. et al. (2024) ‘Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial’, JAMA, 331(1), pp. 38–48. Available at: https://doi.org/10.1001/jama.2023.24945 (Accessed: 4 July 2026).
[3] Rubino, D. et al. (2021) ‘Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial’, JAMA, 325(14), pp. 1414–1425. Available at: https://doi.org/10.1001/jama.2021.3224 (Accessed: 4 July 2026).
[4] National Institute for Health and Care Excellence (2023) Semaglutide for managing overweight and obesity (TA875). Available at: https://www.nice.org.uk/guidance/ta875 (Accessed: 4 July 2026).
[5] National Institute for Health and Care Excellence (2024) Tirzepatide for managing overweight and obesity (TA1026). Available at: https://www.nice.org.uk/guidance/ta1026 (Accessed: 4 July 2026).
